Asia Country Overviews Market Research Reports - Data on Country Overviews in Asia page 1

Printer Format

Region:	All Regions > Asia
Category:	All Categories > Life Sciences > Healthcare > Country Overviews

(114 reports matching your criteria)

Taiwan Pharmaceuticals and Healthcare Report Q3 2013 5/22/2013 \| published by: Business Monitor International ... reduce unnecessary use of medicines. For example, the Bureauof National Health Insurance (BNHI) in Taiwan is cracking down on prescription drugs waste by tighteningits oversight of prescription drug distribution. Therefore, we envisage that main drivers ... \| read more...	$1,295.00
Hong Kong Pharmaceuticals and Healthcare Report Q3 2013 5/22/2013 \| published by: Business Monitor International ... is limited by its small market size and the increasingopenness of the Chinese market, which decreases the necessity for firms to set up bases in Hong Kong. Headline Expenditure Projections Pharmaceuticals: HKD10.31bn (US$1.33bn) in 2012 ... \| read more...	$1,295.00
Japan Pharmaceuticals and Healthcare Report Q3 2013 5/15/2013 \| published by: Business Monitor International ... looking to expand in the country. Meanwhile, domestic firms willcontinue to expand overseas (especially in emerging markets) in order to maintain revenue growth. Headline Expenditure Projections Pharmaceuticals: JPY10,358bn (US$129.7) in 2012 to JPY10,823bn (US$118.9bn) in ... \| read more...	$1,295.00
Pakistan Pharmaceuticals and Healthcare Report Q3 2013 5/15/2013 \| published by: Business Monitor International ... burden over the next two decades -continuing to limit revenue earning opportunities for companies whose product portfolios containmedicines for the treatment of long-term diseases. Headline Expenditure Projections Pharmaceuticals: PKR189.21bn (US$2.03bn) in 2012 to PRK209.65bn (US2.11bn) ... \| read more...	$1,295.00
Indonesia Pharmaceuticals and Healthcare Report Q2 2013 4/24/2013 \| published by: Business Monitor International ... manufacturers and providers of medicalservices. Companies that already have a presence in the South East Asian country will have a distinctadvantage over new entrants. We note that the significant expansion of medical services in recent ... \| read more...	$1,175.00
Russia Pharmaceuticals and Healthcare Report Q2 2013 4/24/2013 \| published by: Business Monitor International ... the market over the last decade has been the growthof the state's role, both in establishing an industrial policy and investing in production for the first timesince the end of the Soviet Union. Key drivers ... \| read more...	$1,175.00
Philippines Pharmaceuticals and Healthcare Report Q2 2013 4/24/2013 \| published by: Business Monitor International ... economic stability, aswell as the eventual implementation of universal healthcare coverage. However, potential threats topolitical stability may threaten overall growth in the sector in terms of policy continuity. Headline Expenditure Projections Pharmaceuticals: PHP129.78bn (US$3.07bn) in ... \| read more...	$1,175.00
Turkey Pharmaceuticals and Healthcare Report Q2 2013 4/17/2013 \| published by: Business Monitor International ... capita spending. However, state intervention in thepharmaceutical sector continues to stifle the industry's potential and restrict foreign drugmakers' accessto the country's lucrative market. Headline Expenditure Projections Pharmaceuticals: TRY16.82bn (US$9.35bn) in 2012 to TRY17.92bn (US$10.10bn) in ... \| read more...	$1,175.00
Sri Lanka Pharmaceuticals and Healthcare Report Q2 2013 4/17/2013 \| published by: Business Monitor International ... 2012 to LKR68.50bn (US$540mn) in 2013; +14.4% in local currency terms and +15.2% in US dollar terms. Healthcare: LKR250.92bn (US$1.97bn) in 2012 to LKR281.13bn (US$2.22bn) in 2013; +12.0% inlocal currency terms and 12.7% in US ... \| read more...	$1,175.00
India Pharmaceuticals and Healthcare Report Q2 2013 4/10/2013 \| published by: Business Monitor International ... prices. Uncertainties in pharmaceuticalregulation, especially in the areas of intellectual property protection, will mean multinationals will remainhesitant to enter this market. For these reasons, we continue to see domestic firms outperforming in India. Headline Expenditure ... \| read more...	$1,175.00
Bangladesh Pharmaceuticals and Healthcare Report Q2 2013 4/10/2013 \| published by: Business Monitor International ... access to medicines and healthcare provision. Moreover, the country's attractiveness to foreign players will continue to be limited due to shortcomingsin its political and regulatory regimes, requiring aid organisations to increase their efforts in the ... \| read more...	$1,175.00
Kazakhstan Pharmaceuticals and Healthcare Report Q2 2013 4/10/2013 \| published by: Business Monitor International ... size of the population and daunting infrastructurechallenges. Pending World Trade Organisation (WTO) accession, expected as soon as this year, as wellas Kazakhstan’s membership in the Customs Union (CU) with Russia and Belarus should drive continuedimprovements ... \| read more...	$1,175.00
Cambodia and Laos Pharmaceuticals and Healthcare Report Q2 2013 3/27/2013 \| published by: Business Monitor International ... markets are highly risky, given the lack ofproper regulation, extensive bureaucracy and rampant corruption. As a consequence, firms looking toexpand in these regions must contend with low or negative sales growth initially. Headline Expenditure Projections ... \| read more...	$1,175.00
Vietnam Pharmaceuticals and Healthcare Report Q2 2013 3/27/2013 \| published by: Business Monitor International ... countries such as China is expected to slowdown as it transits from a developing to a developed country. The current lack of access to healthcaremeant unmet medical needs, which pharmaceutical firms and healthcare providers can ... \| read more...	$1,175.00
Malaysia Pharmaceuticals and Healthcare Report Q2 2013 3/20/2013 \| published by: Business Monitor International ... taken to separate the roles of prescribing anddispensation (currently both tasks are undertaken by doctors), which will give patients greater choice andwill help boost the generic drug sector. Malaysia is also pioneering in the halal ... \| read more...	$1,175.00
China Pharmaceuticals and Healthcare Report Q2 2013 3/13/2013 \| published by: Business Monitor International ... and Novartis. We highlight that companies both domestic and foreignwill continue to benefit from the country's commitment to healthcare. However, a downside risk to thiswould be the government's continued calls for more greater affordability, which ... \| read more...	$1,175.00
Uzbekistan Pharmaceuticals and Healthcare Report Q2 2013 3/13/2013 \| published by: Business Monitor International ... biased in favour of local industries and corruption.Nevertheless, we also expect the market to continue to be reliant on imported pharmaceuticals, withgeneric medicines continuing to meet almost half of the domestic demand. Headline Expenditure Projections ... \| read more...	$1,175.00
Thailand Pharmaceuticals and Healthcare Report Q2 2013 3/13/2013 \| published by: Business Monitor International ... services – the result of an ageing population and agrowing disease burden. Consequently, should the government rein in expenditure (which is necessaryfor the system to be sustainable), consumer contributions towards the cost of healthcare services ... \| read more...	$1,175.00
South Korea Pharmaceuticals and Healthcare Report Q2 2013 3/13/2013 \| published by: Business Monitor International ... the public spending on prescriptiondrugs in Q312 fell by 6.6% year-on-year (y-o-y), although it still accounted for over a quarter of the totalnational health insurance claim costs. As a result, we envisage policies encouraging the ... \| read more...	$1,175.00
Singapore Pharmaceuticals and Healthcare Report Q2 2013 2/27/2013 \| published by: Business Monitor International ... that the innovative nature of the biomedicalsector will attract pharmaceutical firms to set up regional offices, research and development andmanufacturing bases and use it as a base from which to market products to other Asian ... \| read more...	$1,175.00
Cambodia and Laos Pharmaceuticals and Healthcare Report Q1 2013 2/6/2013 \| published by: Business Monitor International ... expected to experience growth at least until 2016 butmobile substitution is becoming an increasing threat, especially when operators step up their ruralexpansion plans. The mobile-over-fixed scenario is also likely to play out in the broadband ... \| read more...	$1,175.00
Vietnam Pharmaceuticals and Healthcare Report Q1 2013 1/30/2013 \| published by: Business Monitor International ... still offers strong growth opportunitiesfor foreign investors. Headline Expenditure Projections Pharmaceuticals: VND50,081bn (US$2.43bn) in 2011 to VND61,910bn (US$2.94bn) in 2012;+23.6% in local currency terms and +21.4% in US dollar terms. Healthcare: VND157, 666bn (US$7.63bn) in ... \| read more...	$1,175.00
Singapore Pharmaceuticals and Healthcare Report Q1 2013 1/30/2013 \| published by: Business Monitor International ... companies looking to set up regionaloffices, manufacturing hubs or research and development facilities in the country given its strongregulatory framework and relatively stable political and economic environment. Headline Expenditure Projections Pharmaceuticals: SGD901mn (US$716mn) in 2011 ... \| read more...	$1,175.00
Singapore Healthcare Industry 2H12 1/14/2013 \| published by: Emerging Markets Direct Reports ... centric initiative, and national electronic health records, plus the profile, comparative matrix and SWOT of the industry leading players: Parkway Holdings Ltd (Parkway), Thomson Medical Centre (TMC), Health Management International Ltd (HMI), and China Healthcare ... \| read more...	$480.00
Indonesia Pharmaceuticals & Healthcare Industry 2H12 1/14/2013 \| published by: Emerging Markets Direct Reports ... support and pharmaceutical trade. It also covers the market trends and outlook, regulatory changes, counterfeit drugs, industry SWOT analysis and market outlook, plus profile, comparative matrix and SWOT analysis of the leading players: PT Kalbe ... \| read more...	$450.00

< prev 1 2 3 4 5 next >